Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies

被引：195

作者：

Eaton L.A. ^{[1
]}

Kalichman S.C. ^{[1
]}

机构：

[1] University of Connecticut, Department of Psychology, Storrs, CT 06269

来源：

Current HIV/AIDS Reports | 2007年 / 4卷 / 4期

关键词：

Sexual Risk Behavior; Male Circumcision; Vira; Risk Compensation; Behavioral Risk Compensation;

D O I：

10.1007/s11904-007-0024-7

中图分类号：

学科分类号：

摘要：

Studies investigating the effects of biologic HIV prevention technologies have been reported with promising results for slowing the spread of the disease. Although they can reduce the rate of HIV transmission at varying levels of efficaciousness, it is vital to anticipate their impact on subsequent sexual behaviors. Risk homeostasis theory posits that decreases in perceived risk, which will occur with access to HIV prevention technologies, will correspond with increases in risk-taking behavior. Here we review the literature on risk compensation in response to HIV vaccines, topical microbicides, antiretroviral medications, and male circumcision. Behavioral risk compensation is evident in response to prevention technologies that are used in advance of HIV exposure and at minimal personal cost. We conclude that behavioral risk compensation should be addressed by implementing adjunct behavioral risk-reduction interventions to avoid negating the preventive benefits of biomedical HIV prevention technologies. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：165 / 172

页数：7

共 55 条

[1]

Cassel M.M., Halperin D.T., Shelton J.D., Stanton D., Risk compensation: The Achilles' heel of innovations in HIV prevention?, Br Med J, 332, pp. 605-607, (2006)

[2]

Wasserheit J.N., Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases, Sex Transm Dis, 19, pp. 61-77, (1992)

[3]

Blower S.M., Gershengorn H.B., Grant R.M., A tale of two futures: HIV and antiretroviral therapy in San Francisco, Science, 287, pp. 650-654, (2000)

[4]

Lui A.Y., Grant R.M., Buchbinder S.P., Preexposure prophylaxis for HIV: Unproven promise and potential pitfalls, JAMA, 206, pp. 863-865, (2006)

[5]

Wilde G.J.S., Target Risk: Dealing with the Danger of Death, Disease, and Damage in Everyday Decisions, (1994)

[6]

HIV/AIDS Prevention Topics

[7]

Massad E., Coutinho F.A.B., Burattini M.N., Et al., The impact of imperfect vaccines on the evolution of HIV virulence, Med Hypotheses, 66, pp. 907-911, (2006)

[8]

Nyamathi A.M., Suhadev M., Swaminathan S., Fahey J.L., Perceptions of a community sample about participation in future HIV vaccine trials in South India, AIDS Behav, 11, pp. 619-627, (2007)

[9]

Chesney M.A., Chambers D.B., Kahn J.O., Risk behavior for HIV infection in participants in preventative HIV vaccine trials: A cautionary note, J Acquir Immune Defic Syndr Hum Retrovirol, 16, pp. 266-271, (1997)

[10]

Crosby R., DiClemente R.J., Mettey A., Correlates of recent unprotected anal sex among men having sex with men attending a large sex resort in the South, Sex Transm Dis, 30, pp. 909-913, (2003)

← 1 2 3 4 5 6 →